OClawVPS.com
Qbic Fund
Edit

Qbic Fund

https://www.qbic.be
Last activity: 18.02.2026
Active
Qbic is a seed and early-stage and sector agnostic inter-university fund investing in spin-offs and young innovating companies that have a technology link with Qbic’s partner universities and research institutions. Qbic is managed by an independent team of seasoned investment and business professionals. The first Qbic fund - Qbic I - was incorporated in 2012 with a capital of € 40,7 million and invested in 18 companies. Qbic I is currently focusing on follow on investments and exits. The second Qbic fund - Qbic II - started in December 2016 and has a capital € of 58,9 million. With in aggregate close to € 100 million under management, Qbic is one of the largest inter-university spin-off funds in Europe.
News
62
Portfolio
6
Persons
20
Mentions
21
Location: Belgium, East Flanders, Ghent
Employees: 11-50
Founded date: 2012
Investment Type: Venture Capital
Investment Stage: Pre-Seed; Seed; Series A; Series B

Portfolio 6

DateNameWebsiteTotal RaisedLocation
02.12.2025AILOS Robo...ailos-robotics.com$4.09MBelgium
04.09.2025MRM Healthmrmhealth.com$64.32MBelgium
26.09.2023Abscint: M...abscint.com$3.18MBelgium, B...
21.12.2021Accelleranaccelleran.com$19.39MBelgium, A...
06.12.2021Trince Biotrincebio.com$15.05MBelgium, E...
06.10.2014Biogazelleservices.biogazelle.com$2.5MBelgium, E...

Persons 20

DateFirst NameLast NameTitleLinkedInLocation
-CédricVan NevelPartner Qb...linkedin.c...-
-SaraVandenwijn...Junior Par...linkedin.c...-
-MarcZabeauManaging P...linkedin.c...-
-SofieBaetenManaging P...linkedin.c...-
-DannyGonnissenPartner Qb...linkedin.c...-
-WimVan CampVenture Pa...linkedin.c...-
-StevenLeuridanPartner Qb...linkedin.c...-
-JohanBrantsAdvisory B...-
-VincentLendersInvestment...linkedin.c...-
-GuyHuylebroec...Partner Qb...linkedin.c...-
Show more

News 62

DateTitleDescription
02.12.2025AILOS Robotics raises €3.5 million in Seed FundingBrussels, Belgium — 02 December 2025 — AILOS Robotics has secured €3.5 million in seed funding to industrialize a new class of actuation for modern, human-centric robots. With a patented gearbox that combines the agility and safety of quasi...
28.11.2025Qbic III provides pre-seed funding to Innocens*Originally published in Dutch. Translated into English for Qbic’s website.* Antwerp, Belgium – November 27th, 2025 – Innocens raises €1.5 million to improve monitoring of premature babies and predict life-threatening infections Neonatologi...
27.11.2025Obulytix Strengthens Senior Leadership with Key Executive and Board AppointmentsGhent, Belgium – November 27th, 2025 – Obulytix, the biotechnology company pioneering Precision Lysin Therapeutics (PLTs) — a novel class of targeted biologics designed as next-generation antibiotics — today announces the appointment of Guy...
04.09.2025MRM Health Raises €55 Million Series BGhent, Belgium – September 04, 2025 – MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced the successful closing of a €55 million ...
28.08.2025Spica Therapeutics secures € 1 Million VLAIO Grant to to advance macrophage-targeted therapiesAntwerp, Belgium - 27 August, 2025 - Spica Therapeutics, a pioneering biotech company focused on harnessing macrophage biology to develop transformative therapies across multiple disease areas, announced today that it has been awarded a €1....
28.08.2025VoxelSensors announces collaboration with Qualcomm TechnologiesBrussels, Belgium, 28 August 2025 - VoxelSensors, a company developing novel intelligent sensing and data insights technology for Physical AI, today announced a collaboration with Qualcomm Technologies, Inc. to jointly optimize VoxelSensors...
27.08.2025Citymesh partners with Accelleran to deploy commercial-grade 5G small cells in urban areasAntwerp, Belgium - 26 August, 2025 - Citymesh and Accelleran are undertaking a joint trial of Open RAN technology to increase the density of 5G networks in urban environments. Starting with lab validation and moving into a large field trial...
01.07.2025Animab Secures EUR 10 Million in Series B FinancingZwijnaarde, 1 July 2025 – Animab (“the Company”), a leader in pioneering first-in-class oral antibody solutions for unmet needs in production animals, announces the successful closing of a EUR 10 million Series B funding round. The investme...
25.06.2025Swave Photonics raises additional €6M Series A Funding from IAG Capital Partners and Samsung VenturesLeuven (Belgium) & Silicon Valley - June 25, 2025 - Swave Photonics, the true holographic display company, today announced an additional €6M ($6.97M) in funding as part of a follow-on investment to the company's Series A round. The fund...
04.06.2025Spica Therapeutics closes € 10 Million seed round to advance macrophage-targeted therapiesAntwerp, Belgium – 4th June, 2025 – Spica Therapeutics (“Spica” or “the Company”), a pioneering biotech company transforming macrophage biology into breakthrough therapies, announced the successful closing of a €10 million Seed financing ro...
Show more

Mentions in press and media 21

DateTitleDescription
18.02.2026Firecell and Accelleran unite in €7.9M-backed merger to simplify private 5G networks5G companies Firecell and Accelleran today announce a merger to create a complete private 5G solution for industrial autonomy, critical infrastructure, and defence connectivity. The merger is backed by a €7.9 million investment round led by...
02.12.2025AILOS Robotics gets €3.5M to scale gearbox manufacturing for Europe’s next-gen robotsBrussels-based AILOS Robotics has raised €3.5 million in a seed round led by QBIC and High-Tech Gründerfonds (HTGF), with participation from Wallonie Entreprendre and finance&invest.brussels, reinforcing Europe’s commitment to developin...
12.09.2025MRM Health: €55 Million Series B Raised For Microbiome-Based Drug CandidatesMRM Health has completed a €55 million Series B financing round that will enable the company to push its microbiome-based drug candidates through critical development milestones and broaden its pipeline of live biotherapeutic products. Bioc...
07.09.2025Belgian Biopharma MRM Health Secures €55 Million to Drive Microbiome Therapeutic InnovationMRM Health, a Belgian biopharma, closed a €55 million Series B financing round. This capital accelerates groundbreaking microbiome-based therapeutics. Lead program MH002 targets ulcerative colitis, entering Phase 2b trials. The proprietary ...
04.09.2025MRM Health Raises €55 Million Series BGhent, Belgium – September 04, 2025 – MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced the successful closing of a €55 million ...
04.09.2025Belgium’s MRM Health raises €55 million for microbiome-based biotherapeutic product pipelineMRM Health, a Ghent-based clinical-stage biopharmaceutical company developing microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced the successful closing of a €55 million Series B financing round. The...
09.07.2025Belgian BioTech developer AmphiStar secures €12.5 million for clean biosurfactantsGent-based biosurfactants developer AmphiStar has secured €12.5 million in funding following the European Innovation Council’s (EIC) latest evaluation round, in order to speed up the production of sustainable microbial biosurfactants, upcyc...
25.04.2024Dutch-based Flindr Therapeutics secures €20M to discover and develop precision oncology therapeuticsRead this article in: Netherlands-based Flindr Therapeutics, a company focused on precision cancer treatments, announced that it has secured €20M in a Series A round of funding. This funding will help advance the Dutch company’s cancer trea...
18.04.2024AmphiStar raises €6M to recycle wasteGhent-based Bioengineering startup Amphistar has raised €6M from European Circular Bioeconomy Fund (ECBF), Qbic III and Flanders Future Tech Fund (FFTF) to derive surfactants from waste. Surfactants play a pivotal role in everyday products ...
26.09.2023ABSCINT raises € 3 million round to initiate Phase II Clinical TrialsBrussels, Liège, September 25, 2023 - ABSCINT has secured EUR 3 million for its technology platform that enables rapid targeting and visualisation of specific molecular markers throughout the entire body via a PET scan. ABSCINT is actively ...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In